Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -

More:
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Related Posts